Stock Blog Hub » Medical Laboratories & Research

(LH) Laboratory Corporation of America Holdings-Orchid Deal Evinces FTC Nod

vitalstocks — Fri, 09 Dec 2011 20:43:56 +0000

Laboratory Corporation of America Holdings (LH) received the much awaited nod from the US Federal Trade Commission (FTC) for the proposed acquisition of Orchid Cellmark (ORCH). The FTC nod comes with the rider that LabCorp will have to hive off certain assets of Orchid’s US government paternity business following completion of the transaction. This would [...]

(LH) Laboratory Corporation of America Holdings-Orchid Deal Evinces FTC Nod

(LH) Laboratory Corporation of America Holdings Extends Orchid Bid Again

vitalstocks — Wed, 07 Dec 2011 17:53:29 +0000

Laboratory Corporation of America Holdings (LH) has once again extended the tender offer for Orchid Cellmark (ORCH) until December 9, 2011. The company had earlier extended the tender offer to November 30. In May 2011, the company received a request from the Federal Trade Commission (FTC) for some additional information related to the transaction. LabCorp [...]

(LH) Laboratory Corporation of America Holdings Extends Orchid Bid Again

(PPDI) Pharmaceutical Product Development Shareholders Nod to Merger

vitalstocks — Tue, 06 Dec 2011 19:34:11 +0000

Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that its shareholders have approved the merger with privately held firms The Carlyle Group and Hellman & Friedman. The merger was announced in October 2011. PPD shareholders have been offered a cash consideration of $33.25 per share. The total purchase consideration comes to $3.9 [...]

(PPDI) Pharmaceutical Product Development Shareholders Nod to Merger

(GHDX) Genomic Health to Showcase Key Data

vitalstocks — Thu, 01 Dec 2011 15:13:57 +0000

Genomic Health (GHDX), an oncology based biotech company, will present results from 16 studies at the San Antonio Breast Cancer Symposium in December. The company has been recording robust revenue growth over the last few quarters banking on its flagship product, Oncotype DX breast cancer test. The test is used for early stage breast cancer [...]

(GHDX) Genomic Health to Showcase Key Data

(DGX) The Future of Healthcare – Personalized Medicine

InvestmentU — Thu, 10 Nov 2011 17:54:49 +0000

by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, November 9, 2011: Issue #1639 I just got back from my annual physical. Fortunately, everything was fine. But my experience solidified my belief that one of the major healthcare trends that will emerge is the concept of personalized medicine. I had been going to the same doctor [...]

(DGX) The Future of Healthcare – Personalized Medicine

(LH) Laboratory Corporation of America Holdings Earnings Scorecard

vitalstocks — Thu, 03 Nov 2011 15:12:33 +0000

The announcement of Laboratory Corporation of America Holdings’ (LH) third quarter fiscal 2011 results, as on October 20, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011. Third Quarter Highlights LabCorp reported adjusted EPS of $1.61 (excluding amortization, restructuring and other special charges) for the third quarter of fiscal [...]

(LH) Laboratory Corporation of America Holdings Earnings Scorecard

(PPDI) Pharmaceutical Product Development to Go Private

vitalstocks — Tue, 11 Oct 2011 15:39:42 +0000

Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that it has entered into an agreement to be acquired by privately held The Carlyle Group and Hellman & Friedman for $3.9 billion in cash. PPD shareholders have been offered a cash consideration of $33.25 per share, a premium of 29.6% over the stock’s [...]

(PPDI) Pharmaceutical Product Development to Go Private

(PPDI) Pharmaceutical Product Development Hires New CEO

vitalstocks — Sat, 24 Sep 2011 18:54:29 +0000

Pharmaceutical Product Development, Inc. (PPDI) recently announced the appointment of Mr. Raymond Hill as its new Chief Executive Officer (CEO) and also a member of the Board of Directors effective from September 16. Raymond Hill was the president of IMS Consulting Group at IMS Health Inc. Prior to joining IMS Health, Mr. Hill served as [...]

(PPDI) Pharmaceutical Product Development Hires New CEO

(LH) Laboratory Corporation of America Holdings-UnitedHealth Extend Pact

vitalstocks — Thu, 15 Sep 2011 17:48:29 +0000

Last week, Laboratory Corporation of America Holdings (LH) announced that it has extended its agreement with UnitedHealthcare Insurance Company, an affiliate of UnitedHealth Group (UNH). The agreement, effective since January 1, 2007, will continue until 2018. Under the terms of the agreement, LabCorp will continue to be the national laboratory for UnitedHealthcare and Oxford Health [...]

(LH) Laboratory Corporation of America Holdings-UnitedHealth Extend Pact

(DGX) Quest Diagnostics Seeks Regular Colon Test

vitalstocks — Wed, 29 Jun 2011 16:37:27 +0000

Leading diagnostics player Quest Diagnostics (DGX) is dissatisfied with the outcome of a nationwide study that it had carried out along with the Colon Cancer Alliance. The data demonstrated that one in three of men and women aged 60-70 have been screened for colon cancer only once. However, the medical guidelines suggest periodic testing after [...]

(DGX) Quest Diagnostics Seeks Regular Colon Test

(DGX) Quest Diagnostics Launches Gazelle on Android

vitalstocks — Thu, 23 Jun 2011 16:08:33 +0000

Quest Diagnostics (DGX),a leading player in the diagnostic testing market, recently launched a new version of its mobile health platform, Gazelle. The company claims that this latest version will work in sync with Google’s (GOOG) fast-growing Android smartphone operating system. Currently, Gazelle is available for free at Gazelleapp.com as well as in the Android Market [...]

(DGX) Quest Diagnostics Launches Gazelle on Android

(LH) Laboratory Corporation of America Holdings Extends Orchid Tender Offer

vitalstocks — Sun, 19 Jun 2011 13:34:08 +0000

Laboratory Corporation of America Holdings (LH) has decided to extend the tender offer for Orchid Cellmark (ORCH) till July 15, 2011. Earlier, in May 2011, the company received a request from the Federal Trade Commission (FTC) for some additional information related to the transaction. LabCorp is cooperating with the FTC on this issue. Till date [...]

(LH) Laboratory Corporation of America Holdings Extends Orchid Tender Offer

(PPDI) Pharmaceutical Product Development Misses Estimates by a Penny

vitalstocks — Tue, 03 May 2011 19:09:46 +0000

Pharmaceutical Product Development, Inc. (PPDI) reported first quarter 2011 earnings of 32 cents per share, above the year-ago earnings of 14 cents per share. Earnings growth was driven by higher revenue, improved gross margins and reduced SG&A expenses. Earnings however came a penny below the Zacks Consensus Estimate of 33 cents. Quarterly revenue of $383.2 [...]

(PPDI) Pharmaceutical Product Development Misses Estimates by a Penny

(DGX) Quest Diagnostics Expedites Celera Acquisition

vitalstocks — Fri, 15 Apr 2011 17:01:06 +0000

Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The company recently announced that the waiting period under the HSR Act has expired, though some other conditions are yet to be met. The tender offer to acquire the shares of Celera is supposed to close on [...]

(DGX) Quest Diagnostics Expedites Celera Acquisition

(DGX) Quest Diagnostics – Bear of the Day

vitalstocks — Mon, 02 Aug 2010 14:51:20 +0000

Quest Diagnostics (DGX) second-quarter EPS of $0.89 beats the Zacks Consensus Estimate by a penny and the year-ago quarters by 7 cents. However, revenues declined 1.4% to $1.9 billion, driven by a decline in both volume and pricing. Meanwhile, the company proactively negotiated contracts with some MCOs at reduced prices. Although this gives more visibility, [...]

(DGX) Quest Diagnostics – Bear of the Day

(GHDX) Genomic Heath Incorporated – Bear of the Day

vitalstocks — Fri, 23 Jul 2010 15:09:32 +0000

Genomic Health’s (GHDX) first quarter 2010 loss of $0.07 per share missed the Zacks Consensus Estimate of a loss of $0.03. Although the company’s lead product, Oncotype DX breast cancer test, recorded a year-over-year growth of 20%, revenues declined sequentially. Meanwhile, Genomic launched its colon cancer test in January 2010, though this test will take [...]

(GHDX) Genomic Heath Incorporated – Bear of the Day

(LH) LabCorp First Quarter 2010 Earnings Scorecard

vitalstocks — Mon, 24 May 2010 04:13:55 +0000

First Quarter Highlights On April 21, LabCorp (LH) reported first quarter fiscal 2010 earnings per share (EPS) of $1.25 compared with earnings of $1.22 in the year-ago period. However, after considering restructuring and other special charges, the company’s EPS came in at $1.30, missing the Zacks Consensus Estimate by a penny. Revenues recorded a 3.3% [...]

(LH) LabCorp First Quarter 2010 Earnings Scorecard

(GHDX) Genomic Health’s Loss Wider Than Expected

vitalstocks — Thu, 06 May 2010 20:31:39 +0000

Genomic Health Inc’s (GHDX) first quarter 2010 loss of 7 cents per share was wider than the Zacks Consensus Estimate of a net loss of 3 cents. The company had suffered a loss of 16 cents in the prior-year period. Total revenues for the reported quarter came in at $41.2 million as against $33.9 million [...]

(GHDX) Genomic Health’s Loss Wider Than Expected

(ARRY) Array BioPharma and Novartis AG Sign Deal for Treating Cancer

vitalstocks — Thu, 22 Apr 2010 21:27:24 +0000

Recently, Array BioPharma Inc. (ARRY) struck a deal with Novartis AG (NVS) to develop its small-molecule methyl ethyl ketone (MEK) inhibitors for treating cancer. The transaction is worth up to $467 million. Array is entitled to receive $45 million in upfront and milestone payments and a further $422 million subject to the achievement of other [...]

(ARRY) Array BioPharma and Novartis AG Sign Deal for Treating Cancer

(LH) Laboratory Corporation of America Holdings Misses by a Penny

vitalstocks — Thu, 22 Apr 2010 20:10:26 +0000

Laboratory Corporation of America Holdings (LH) reported first quarter fiscal 2010 earnings per share (EPS) of $1.25 compared to earnings of $1.22 reported in the year-ago period. However, after considering restructuring and other special charges, the company’s EPS came in at $1.30, missing the Zacks Consensus Estimate by a penny. Revenues recorded a 3.3% year-over-year [...]

(LH) Laboratory Corporation of America Holdings Misses by a Penny

(DGX) Quest Diagnostics Beats Expectations but Revenues are Unchanged

vitalstocks — Wed, 21 Apr 2010 20:58:23 +0000

Quest Diagnostics (DGX) reported first quarter fiscal 2010 earnings per share (EPS) of 89 cents, unchanged from the year-ago period. However, excluding the impact of severe weather conditions and charges associated with workforce reduction Quest’s EPS came in at $1.00, beating the Zacks Consensus Estimate by a couple of cents. Revenues for the quarter remained [...]

(DGX) Quest Diagnostics Beats Expectations but Revenues are Unchanged

(DGX) Why Healthcare Reform Should Help The Diagnostics Industry

InvestmentU — Thu, 01 Apr 2010 21:37:50 +0000

America seems to be divided into two camps… Not blue states versus red states. Not Yankees fans versus Red Sox fans (although why you’d be the latter I’ll never understand). Not even people who support the new healthcare reform bill versus those who are opposed to it. Rather, I’m talking about the difference between people [...]

(DGX) Why Healthcare Reform Should Help The Diagnostics Industry

(GHDX) Genomic Health Announces New Distribution Deal

vitalstocks — Mon, 29 Mar 2010 20:52:03 +0000

Recently, Genomic Health, Inc. (GHDX) announced that it has agreed to distribute its breast cancer assay Oncotype DX with Palex Medical S.A. in Spain and Portugal. The company also announced encouraging data on Oncotype DX at the 7th European Breast Cancer Conference in Barcelona. The deal with Palex Medical, a leading player in the distribution [...]

(GHDX) Genomic Health Announces New Distribution Deal

(BRLI) Bio-Reference Labs – Analysts React By Raising Estimates

vitalstocks — Mon, 29 Mar 2010 16:45:07 +0000

Bio-Reference Labs (BRLI) recently beat earnings estimates once again. Shares are up roughly 10% since being featured as a Zacks Rank Buy in December. Company Description Bio-Reference Laboratories, provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company was founded in 1981 and has a market [...]

(BRLI) Bio-Reference Labs – Analysts React By Raising Estimates

(SPEX) Initiating Spherix Analyst Coverage at Outperform

vitalstocks — Tue, 09 Feb 2010 21:35:33 +0000

We are initiating coverage of Spherix, Inc. (SPEX) with an Outperform rating and price target of $3.50 per share. We are optimistic about D-tagatose, a functional sweetener and a naturally occurring L-epimer of D-Fructose currently under phase III development for the treatment of type 2 diabetes. D-tagatose, or Naturlose as it is branded, was originally [...]

(SPEX) Initiating Spherix Analyst Coverage at Outperform

(ARRY) Array BioPharma Incorporated Reports Lower Second Quarter Loss

vitalstocks — Wed, 03 Feb 2010 01:37:52 +0000

Array BioPharma Inc’s (ARRY) second quarter fiscal 2010 net loss came in at $21.8 million, or 44 cents per share, which was lower than the Zacks Consensus Estimate of a net loss of 55 cents. The company suffered a loss of $37.8 million, or 79 cents a share, in the year-ago quarter. The narrower loss [...]

(ARRY) Array BioPharma Incorporated Reports Lower Second Quarter Loss

(DGX) Quest Diagnostics Beats Expectations – Guides In-Line

vitalstocks — Mon, 25 Jan 2010 20:52:44 +0000

Quest Diagnostics’ (DGX) fourth quarter earnings per share of 97 cents beat both the Zacks Consensus Estimate by a penny and the 87 cents reported in the year-ago period. Revenues for the quarter increased 2.7% to $1.8 billion. Clinical testing revenues, which account for most of Quest’s sales Incorporatedreased 2.3% compared to the prior year. [...]

(DGX) Quest Diagnostics Beats Expectations – Guides In-Line

(GHDX) Genomic Health Announces Commercial Availability Of Its Oncotype DX Colon Cancer Test

vitalstocks — Sat, 23 Jan 2010 21:18:02 +0000

Recently, Genomic Health, Inc. (GHDX) announced the global commercial availability of its Oncotype DX colon cancer test. The 12-gene diagnostic test aims to predict individual recurrence risk in stage II colon cancer patients after surgery. The Genomic Health test is the first multigene expression test developed for assessing the risk of recurrence in patients suffering [...]

(GHDX) Genomic Health Announces Commercial Availability Of Its Oncotype DX Colon Cancer Test

(GHDX) Genomic Health Provides Revenue Guidance

vitalstocks — Fri, 08 Jan 2010 21:01:58 +0000

Genomic Health, Inc. (GHDX) announced recently that it is confident of meeting the annual revenue guidance for the fiscal year 2009, ended Dec 31. The company expects to report revenues of $149.5 million for fiscal 2009. This represents a 35% increase on revenues of $110.6 million reported by Genomic Health in fiscal 2008. Genomic Health [...]

(GHDX) Genomic Health Provides Revenue Guidance

(BRLI) Bio-Reference Labs – Earnings Estimates Are Rising

vitalstocks — Wed, 30 Dec 2009 21:54:14 +0000

Bio-Reference Laboratories (BRLI) is setting new 52-week highs following its record-breaking quarter. Company Description Bio-Referance Laboratories, provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company was founded in 1981 and has a market cap of $536 million. Record-Setting Quarter On Dec 17 the company reported [...]

(BRLI) Bio-Reference Labs – Earnings Estimates Are Rising

(GXDX) Genoptix, Inc. – Sales Were up 58% From Last Year

vitalstocks — Wed, 16 Dec 2009 17:24:14 +0000

Genoptix, Inc. (GXDX) continues to pressure its 52-week high as shares ride a trend line that began this summer higher. The company’s better than expected third-quarter results, reported on Nov 5, also helped fuel optimism. Company Description Genoptix, Inc. provides specialized laboratory services focusing on diagnostics in the United States. The company was founded in [...]

(GXDX) Genoptix, Inc. – Sales Were up 58% From Last Year

(ARRY) Array BioPharma Sees Positive Results for ARRY-380

vitalstocks — Tue, 15 Dec 2009 01:21:10 +0000

Recently, Array BioPharma Inc. (ARRY) announced positive interim results on its inhibitor, ARRY-380, from an early-stage, open-label, multiple dose trial in patients with advanced cancer. The company presented the results at the 2009 San Antonio Breast Cancer Symposium. The study is designed to evaluate the safety, tolerability and pharmacokinetics of ARRY-380 following daily oral administration [...]

(ARRY) Array BioPharma Sees Positive Results for ARRY-380

(GHDX) Genomic Health, Inc Reveals Oncotype DX Data

vitalstocks — Fri, 11 Dec 2009 22:48:37 +0000

Genomic Health, Inc. (GHDX) announced that positive results were published in the journal, The Lancet Oncology, from a study of the company’s growth engine, Oncotype DX, in postmenopausal women suffering from node-positive, estrogen receptor-positive breast cancer. The study was conducted by the Southwest Oncology Group (SWOG) and funded by the National Cancer Institute and Genomic [...]

(GHDX) Genomic Health, Inc Reveals Oncotype DX Data

(GHDX) Genomic Health Third Quarter Loss Narrows

vitalstocks — Mon, 09 Nov 2009 02:46:09 +0000

Genomic Health Inc. (GHDX) suffered a third quarter loss of 2 cents per share, which was better than the Zacks Consensus Estimate of a loss of 9 cents. The company suffered a loss of 11 cents in the prior-year period. Total revenues for the quarter came in at $39.5 million, compared with $28.1 million in [...]

(GHDX) Genomic Health Third Quarter Loss Narrows

(DGX) Quest Diagnostics Outperforms – Raises Outlook

vitalstocks — Wed, 21 Oct 2009 23:47:48 +0000

Quest Diagnostics’ (DGX) third quarter earnings per share of $1.02 beat the Zacks Consensus Estimate of 96 cents and 86 cents reported in the year ago period. Revenues for the quarter increased 3.9% to $1.9 billion. Clinical testing revenues, which account for most of Quest’s sales increased 4.3% compared to the prior year. Quest Diagnostics [...]

(DGX) Quest Diagnostics Outperforms – Raises Outlook

(GHDX) Genomic Health’s Results Reveal Oncotype DX Utility

vitalstocks — Wed, 14 Oct 2009 16:28:00 +0000

Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage breast cancer. Genomic Health’s Oncotype DX is the only commercially available breast cancer test that makes use of [...]

(GHDX) Genomic Health’s Results Reveal Oncotype DX Utility

(ARRY) Setback for Array BioPharma’s Drug

vitalstocks — Tue, 08 Sep 2009 23:24:32 +0000

Last week, Array BioPharma (ARRY) announced that its most advanced, wholly-owned MEK inhibitor, ARRY-162, which was being developed to treat rheumatoid arthritis patients, failed to achieve a better response than placebo in a mid-stage trial. The study was designed to assess ARRY-162 in 201 patients with active rheumatoid arthritis who were not completely responsive to [...]

(ARRY) Setback for Array BioPharma’s Drug

(GHDX) Good News for Genomic Health

vitalstocks — Fri, 04 Sep 2009 23:17:10 +0000

Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health’s Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about treatment options available at their maiden visit to an oncologist. Oncotype DX, the growth engine [...]

(GHDX) Good News for Genomic Health

(ARRY) Array Meets Expectations

vitalstocks — Thu, 20 Aug 2009 18:33:58 +0000

Last week, Array BioPharma Inc. (ARRY) reported a fourth-quarter net loss of 55 cents per share which was in line with the Zacks Consensus Estimate. The company had a loss of 68 cents in the year-ago quarter. Net loss for fiscal 2009 was $2.67 per share, compared with $2.04 last year. Quarterly revenue came in [...]

(ARRY) Array Meets Expectations

(BRLI) Bio-Reference Laboratories Inc. – In spite of the weak economy, revenue was up 16% from last year

Shawn — Thu, 23 Jul 2009 18:53:54 +0000

Bio-Reference Laboratories Inc. (BRLI) is posting impressive gains in response to strong revenue growth and expanding margins. Company Description Bio-Reference Laboratories, provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company was founded in 1981 and has a market cap of $436 million. Shares of BRLI [...]

(BRLI) Bio-Reference Laboratories Inc. – In spite of the weak economy, revenue was up 16% from last year

(DGX) Quest Diagnostics Incorporated – Growth And Income – Zacks Rank Buy

vitalstocks — Thu, 30 Apr 2009 20:31:54 +0000

Quest Diagnostics Incorporated (DGX) recently delivered strong first-quarter results. Earnings per share of 89 cents topped the year-prior 72 cents and exceeded analysts’ expectations by 8.5%. Company Description Quest Diagnostics Incorporated provides diagnostic testing, information and services for patients and doctors all over the world. The company offers the broadest access to diagnostic testing services [...]

(DGX) Quest Diagnostics Incorporated – Growth And Income – Zacks Rank Buy

(BRLI) Bio-Reference Laboratories – This was the second consecutive quarter that the company has surprised and beat estimates

Shawn — Fri, 26 Dec 2008 23:49:19 +0000

Bio-Reference Laboratories, Inc. (BRLI) share price has been rallying since the company reported excellent fourth-quarter and full-year results last week. The next-year estimate has held steady, pegged at $1.48 per share, a n 8.5% earnings growth projection. Company Description Bio-Reference Laboratories, Inc. provides clinical laboratory testing services primarily in the greater New York metropolitan area. [...]

(BRLI) Bio-Reference Laboratories – This was the second consecutive quarter that the company has surprised and beat estimates